Both studies showed highly significant reductions in the primary outcome of HHF or cardiovascular death irrespective of baseline kidney function, proteinuria, gender, race, diabetic status.
← all excerpts
The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
1
—
—